Annual report
3583.TEDINET S100R1FM
Period2022-04-01 → 2023-03-31
Filed2023-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥4.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥623m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥707m | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥639m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥727m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥332m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥203m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥429m | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥681m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥726m | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥469m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥537m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥115m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥141m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥318m | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥469m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥537m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥9.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥9.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥8.6bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.5bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.7bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.5bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥4.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.8bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.8bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥4.8bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥4.7bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.4bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.4bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.4bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥338m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥631m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥279m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥509m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥184m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥189m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥182m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥139m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥173m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥206m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥266m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥13m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥89m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥339m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥169.17 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥194.04 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.6 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥50.89 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.17 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,100.85 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,957.25 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,753.19 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,724.32 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,708.06 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 62.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.1% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.5% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.3% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.4% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 340 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 364 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 350 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 423 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 424 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥5.0bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥5.3bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥4.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥485m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥571m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥492m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥619m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥246m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥132m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥337m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥531m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥616m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥368m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥440m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥190m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥95m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥250m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.5bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥8.7bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥8.0bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.8bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.9bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.3bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥3.9bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥5.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.4bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.0bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥132.59 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥159.25 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.67 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.29 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.69 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥20 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,843.5 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,736.4 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,580.8 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,533.57 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,525.76 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 60.5% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.4% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.4% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.2% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 3,092,623 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 130 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 132 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 130 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 129 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 131 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 81
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥22,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥24m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥344,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥24m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | −¥8m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥432,000 |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥11m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥28m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥28m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥303m |
| Medical Productsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥40m |
| Medical Productsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥55m |
| Medical Productsreportable segment | employees | at 2023-03-31 | 50 pure |
| Medical Productsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Medical Productsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Medical Productsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥4m |
| Medical Productsreportable segment | segment assets | at 2023-03-31 | ¥1.3bn |
| Medical Productsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥102m |
| Technological Productsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥166m |
| Technological Productsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥231m |
| Technological Productsreportable segment | employees | at 2023-03-31 | 278 pure |
| Technological Productsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥3.9bn |
| Technological Productsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥3.9bn |
| Technological Productsreportable segment | segment assets | at 2023-03-31 | ¥5.7bn |
| Technological Productsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥832m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥205m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥287m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥5.3bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥5.3bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥4m |
| —segment total | segment assets | at 2023-03-31 | ¥7.0bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥934m |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥205m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥287m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥5.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥5.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥28m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥926m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥299,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥14m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥12m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥36m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | −¥20m |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥3m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥12m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥16m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥16m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥306m |
| Medical Productsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥64m |
| Medical Productsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥48m |
| Medical Productsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| Medical Productsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| Medical Productsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥4m |
| Medical Productsreportable segment | segment assets | at 2022-03-31 | ¥1.4bn |
| Medical Productsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥147m |
| Technological Productsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥220m |
| Technological Productsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥229m |
| Technological Productsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥4.1bn |
| Technological Productsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥4.1bn |
| Technological Productsreportable segment | segment assets | at 2022-03-31 | ¥5.7bn |
| Technological Productsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥886m |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥284m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥277m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥5.5bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥5.5bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥4m |
| —segment total | segment assets | at 2022-03-31 | ¥7.1bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥284m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥277m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥16m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥7.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| Medical Productsreportable segment | employees | at 2023-03-31 | 16 pure |
| Technological Productsreportable segment | employees | at 2023-03-31 | 102 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,565
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 3894027000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 1420847000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReportableSegmentsMember | 5314875000 | JPY |
| Revenues from external customers | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 344000 | JPY |
| Revenues from external customers | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 5315220000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 5315220000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 4267000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReportableSegmentsMember | 4267000 | JPY |
| Transactions with other segments | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 24000000 | JPY |
| Transactions with other segments | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 28267000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | -28267000 | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 3894027000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 1425115000 | JPY |
| Net sales | CurrentYearDuration_ReportableSegmentsMember | 5319143000 | JPY |
| Net sales | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 24344000 | JPY |
| Net sales | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 5343488000 | JPY |
| Net sales | CurrentYearDuration_ReconcilingItemsMember | -28267000 | JPY |
| Net sales | CurrentYearDuration | 5315220000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 831772000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 102161000 | JPY |
| Operating income | CurrentYearDuration_ReportableSegmentsMember | 933934000 | JPY |
| Operating income | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -7844000 | JPY |
| Operating income | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 926090000 | JPY |
| Operating income | CurrentYearDuration_ReconcilingItemsMember | -302964000 | JPY |
| Operating income | CurrentYearDuration | 623125000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 5684015000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 1332130000 | JPY |
| Assets | CurrentYearInstant_ReportableSegmentsMember | 7016145000 | JPY |
| Assets | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Assets | CurrentYearInstant_TotalOfReportableSegmentsAndOthersMember | 7016145000 | JPY |
| Assets | CurrentYearInstant_ReconcilingItemsMember | 2311868000 | JPY |
| Assets | CurrentYearInstant | 9328014000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 231441000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 55253000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReportableSegmentsMember | 286695000 | JPY |
| Depreciation segment information | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 22000 | JPY |
| Depreciation segment information | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 286718000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReconcilingItemsMember | 10579000 | JPY |
| Depreciation segment information | CurrentYearDuration | 297297000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 165724000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 39662000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_ReportableSegmentsMember | 205386000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 205386000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_ReconcilingItemsMember | 432000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration | 205819000 | JPY |
| Cash and deposits | Prior1YearInstant_NonConsolidatedMember | 1987062000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |